Mapping lung cancer genes to unlock future treatments
NCT ID NCT02688894
First seen Jun 24, 2026 · Last updated Aug 13, 2026 · Updated 3 times
Summary
This study analyzes tumor tissue from 797 people with relapsed small cell lung cancer to identify genetic subtypes. No drugs are tested here. Instead, the results may help match patients to future targeted therapy trials. Participants must have had prior platinum-based chemotherapy and provide tissue samples.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this screening could identify which genetic subtypes of small cell lung cancer exist, paving the way for more personalized treatment trials.
- What could go wrong
- This is only a screening study, not a treatment. It does not test any drug, so there is no direct benefit to participants. Results may not lead to effective therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE; CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chungbuk University Hospital
COMPLETEDTaebuk, South Korea
-
Gachon University Gil Medical Center
COMPLETEDIncheon, South Korea
-
Samsung Medical Center
RECRUITINGSeoul, 135-710, South Korea
-
Seoul National University Bundang Hospital
COMPLETEDSeongnam, South Korea
-
Ulsan University Hospital
COMPLETEDUlsan, South Korea
-
VHS Medical Center
COMPLETEDSeoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a black seed extract boost immunotherapy against a rare cancer?
- New drug cocktail aims to fight rare cancer
- Double-Action antibody takes on Hard-to-Treat neuroendocrine cancers
- Two-Drug combo aims to stall rare gut tumors
- Could a PARP inhibitor boost chemo for tough lung cancer?
- New drug ZG006 takes on chemo in advanced cancer battle